U.S. Markets close in 1 hr 13 mins

LeMaitre Vascular, Inc. (LMAT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
61.32+2.36 (+4.00%)
As of 2:46PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close58.96
Open58.88
Bid60.99 x 1000
Ask61.06 x 1100
Day's Range58.74 - 61.45
52 Week Range23.81 - 61.45
Volume88,633
Avg. Volume117,942
Market Cap1.263B
Beta (5Y Monthly)1.34
PE Ratio (TTM)52.86
EPS (TTM)1.16
Earnings DateJul 21, 2021 - Jul 26, 2021
Forward Dividend & Yield0.44 (0.88%)
Ex-Dividend DateMay 18, 2021
1y Target Est59.80
  • LeMaitre to Present at the Goldman Sachs Virtual Global Healthcare Conference
    GlobeNewswire

    LeMaitre to Present at the Goldman Sachs Virtual Global Healthcare Conference

    BURLINGTON, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that David Roberts, President, will present at the Goldman Sachs 42nd Annual Virtual Global Healthcare Conference on Thursday, June 10, 2021, at 5:30 PM ET. LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and im

  • At US$51.50, Is It Time To Put LeMaitre Vascular, Inc. (NASDAQ:LMAT) On Your Watch List?
    Simply Wall St.

    At US$51.50, Is It Time To Put LeMaitre Vascular, Inc. (NASDAQ:LMAT) On Your Watch List?

    LeMaitre Vascular, Inc. ( NASDAQ:LMAT ), is not the largest company out there, but it saw a double-digit share price...

  • LeMaitre Regains Five CE Marks
    GlobeNewswire

    LeMaitre Regains Five CE Marks

    BURLINGTON, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today announced that it received CE marks under the European Medical Devices Directive (93/42/EC as amended by 2007/47/EC) for the following five products. Marks for the five products had previously lapsed due to a change in notified bodies. ProductNotified BodyExpiration DateXenoSure Biologic PatchesTUV SUDMay 26, 2024AlboGraft Polyester Vascular GraftsTUV SUDMay 26, 2024Pruitt Carotid ShuntsSGSMay 24, 2024Flexcel Carotid ShuntsSGSMay 24, 2024AnastoClip Closure SystemsSGSMay 24, 2024 The indications for use under the new CE mark for XenoSure no longer include neuro or cardiac applications, indications for which the product was approved under its prior CE mark. Additionally, only XenoSure made from bovine pericardium sourced from certain of our suppliers is permitted to be sold under the new CE mark. Andrew Hodgkinson, SVP of Clinical, Regulatory & Quality Affairs, said, “While our customers have largely enjoyed uninterrupted supply of most of these devices due to inventory stockpiles and local derogations, we are pleased to have received these five CE marks before the transition to the new Medical Device Regulation in the EU on May 26, 2021. We emerge from this transition having lost CE marks on several smaller product lines totaling just 3% of our 2019 EMEA sales.” About LeMaitre LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. LeMaitre is a registered trademark of LeMaitre Vascular, Inc. This press release may include other trademarks and trade names of the Company. For more information about the Company, please visit http://www.lemaitre.com. CONTACT: Contact: Sandra Millar LeMaitre Vascular, Inc. +1-781-425-1686 smillar@lemaitre.com